(ABCL) Abcellera Biologics - Overview
Stock: Antibody, Drug, Candidate, Preclinical, Pipeline
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 67.5% |
| Relative Tail Risk | -8.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -32.12 |
| Character TTM | |
|---|---|
| Beta | 1.488 |
| Beta Downside | 1.127 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.66% |
| CAGR/Max DD | -0.43 |
Description: ABCL Abcellera Biologics January 20, 2026
AbCellera Biologics Inc. (NASDAQ: ABCL) is a Canadian-based biotech that leverages its proprietary antibody-discovery platform to develop therapeutic antibodies for U.S. indications lacking effective treatments.
The current pipeline is early-stage: ABCL635, an antibody-drug conjugate targeting metabolic and endocrine disorders, and ABCL575, a half-life-extended fully human monoclonal antibody aimed at T-cell-mediated autoimmune diseases such as atopic dermatitis. Both candidates remain in pre-clinical testing, meaning they face the typical high attrition risk associated with this development phase.
Strategic collaborations underpin the company’s R&D engine: a research and license agreement with Eli Lilly provides access to large-scale development resources, while partnership deals with Biogen and investment firms Viking Global Investors & ArrowMark Partners supply both capital and potential co-development pathways.
As of the latest filing (Q4 2024), ABCL reported a market capitalization of roughly $300 million and a cash balance of about $150 million, giving it ~12 months of runway at current burn rates. The broader biotech sector is being driven by rising demand for antibody therapeutics-global antibody sales are projected to exceed $200 billion by 2028-and by sustained venture and public-market funding, which together improve financing conditions for early-stage players like AbCellera.
If you’re evaluating high-conviction biotech opportunities, a quick look at ValueRay’s analyst notes on ABCL can help surface additional quantitative insights and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -171.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 2.83 > 1.0 |
| NWC/Revenue: 1773 % < 20% (prev 2012 %; Δ -239.2% < -1%) |
| CFO/TA -0.08 > 3% & CFO -104.6m > Net Income -171.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (298.9m) vs 12m ago 1.36% < -2% |
| Gross Margin: -79.64% > 18% (prev -1.80%; Δ -7784 % > 0.5%) |
| Asset Turnover: 2.57% > 50% (prev 2.37%; Δ 0.20% > 0%) |
| Interest Coverage Ratio: -27.21 > 6 (EBITDA TTM -186.3m / Interest Expense TTM 8.05m) |
Altman Z'' 3.98
| A: 0.46 (Total Current Assets 695.1m - Total Current Liabilities 68.8m) / Total Assets 1.36b |
| B: -0.02 (Retained Earnings -20.5m / Total Assets 1.36b) |
| C: -0.16 (EBIT TTM -219.1m / Avg Total Assets 1.37b) |
| D: 1.97 (Book Value of Equity 771.2m / Total Liabilities 392.0m) |
| Altman-Z'' Score: 3.98 = AA |
Beneish M -2.06
| DSRI: 2.35 (Receivables 159.4m/63.2m, Revenue 35.3m/33.0m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.75 (AQ_t 0.17 / AQ_t-1 0.23) |
| SGI: 1.07 (Revenue 35.3m / 33.0m) |
| TATA: -0.05 (NI -171.7m - CFO -104.6m) / TA 1.36b) |
| Beneish M-Score: -2.06 (Cap -4..+1) = BB |
What is the price of ABCL shares?
Over the past week, the price has changed by -27.98%, over one month by -18.95%, over three months by -40.72% and over the past year by -17.75%.
Is ABCL a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABCL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.8 | 253.6% |
| Analysts Target Price | 9.8 | 253.6% |
| ValueRay Target Price | 2 | -26.6% |
ABCL Fundamental Data Overview February 03, 2026
P/S = 30.675
P/B = 1.1985
Revenue TTM = 35.3m USD
EBIT TTM = -219.1m USD
EBITDA TTM = -186.3m USD
Long Term Debt = 142.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.17m USD (from shortTermDebt, last quarter)
Debt = 142.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 59.1m USD (from netDebt column, last quarter)
Enterprise Value = 730.1m USD (1.08b + Debt 142.2m - CCE 495.7m)
Interest Coverage Ratio = -27.21 (Ebit TTM -219.1m / Interest Expense TTM 8.05m)
EV/FCF = -4.77x (Enterprise Value 730.1m / FCF TTM -153.1m)
FCF Yield = -20.97% (FCF TTM -153.1m / Enterprise Value 730.1m)
FCF Margin = -433.4% (FCF TTM -153.1m / Revenue TTM 35.3m)
Net Margin = -486.0% (Net Income TTM -171.7m / Revenue TTM 35.3m)
Gross Margin = -79.64% ((Revenue TTM 35.3m - Cost of Revenue TTM 63.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 58.68%)
Tobins Q-Ratio = 0.54 (Enterprise Value 730.1m / Total Assets 1.36b)
Interest Expense / Debt = 5.66% (Interest Expense 8.05m / Debt 142.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -173.1m (EBIT -219.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.10 (Total Current Assets 695.1m / Total Current Liabilities 68.8m)
Debt / Equity = 0.15 (Debt 142.2m / totalStockholderEquity, last quarter 964.0m)
Debt / EBITDA = -0.32 (negative EBITDA) (Net Debt 59.1m / EBITDA -186.3m)
Debt / FCF = -0.39 (negative FCF - burning cash) (Net Debt 59.1m / FCF TTM -153.1m)
Total Stockholder Equity = 1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = -12.49% (Net Income -171.7m / Total Assets 1.36b)
RoE = -16.95% (Net Income TTM -171.7m / Total Stockholder Equity 1.01b)
RoCE = -18.97% (EBIT -219.1m / Capital Employed (Equity 1.01b + L.T.Debt 142.2m))
RoIC = -17.09% (negative operating profit) (NOPAT -173.1m / Invested Capital 1.01b)
WACC = 10.60% (E(1.08b)/V(1.23b) * Re(11.40%) + D(142.2m)/V(1.23b) * Rd(5.66%) * (1-Tc(0.21)))
Discount Rate = 11.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.35%
Fair Price DCF = unknown (Cash Flow -153.1m)
EPS Correlation: -52.62 | EPS CAGR: -29.28% | SUE: 4.0 | # QB: 1
Revenue Correlation: -78.93 | Revenue CAGR: -51.90% | SUE: 0.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.18 | Chg30d=-0.040 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.69 | Chg30d=-0.185 | Revisions Net=+1 | Growth EPS=-5.8% | Growth Revenue=+56.2%